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Abstract Hepatitis B virus (HBV) is an etiological agent
of viral hepatitis, which may lead to cirrhosis, and hepa-
tocellular carcinoma. Current treatment strategies have not
shown promising effect to date but various complications
such as, drug toxicity-resistance have been reported. Study
on newly discovered compounds, with minimal side
effects, as specific HBV inhibitors is a fundamental subject
introducing new biologic drugs. Here, we aimed to, by
prediction, estimate interactions of HBF-0259 as a non-
toxic anti-HBV compound on inhibiting the HBV through
either interaction with the viral entry or HBsAg secreting
factors using In Silico procedure. Molecular docking was
performed by Hex 8.0.0 software to predict the interaction
energy (Etot) between HBF-0259 and known cellular fac-
tors involved in HBV entry and HBsAg secreting factors.
Hex 8.0.0 also employed to create protein–protein com-
plexes. These interactions were then used to analyze the
binding site of HBF-0259 within the assumed receptors by
MGLTools software. Finally, the amino acid sequences
involved in this interaction were aligned for any conser-
vancy. Here, we showed that HBF-0259 Etot with CypA
(-545.41 kcal/mol) and SCCA1 (499.68 kcal/mol),
involved in HBsAg secretion and HBV integration,
respectively, was higher than other interactions. Further-
more, HBF-0259 predicted interaction energy was even
higher than those of CypA inhibitors. In addition, we claim
that preS1 and/or preS2 regions within HBsAg are not
suitable targets for HBF-0259. HBF-0259 has higher
interaction energy with CypA and SCCA1, even more than
other known receptors, co-receptors, viral ligands, and
secretory factors. HBF-0259 could be introduced as potent
anti-viral compound in which CypA and or SCCA1, as
previously shown, are involved.
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Introduction
Hepatitis B Virus (HBV) is a causative agent of viral
hepatitis, cirrhosis, and hepatocellular carcinoma (HCC)
with a relatively high prevalence all around the world [32].
As the untreated chronic infections may result in HCC, the
treatment is crucial. The majority of current treatment
strategies have shown to be helpless in complete removal
of the pathogenic agent. Several FDA-approved common
agents have shown no promising efficacy upon restricting
HBV. Moreover, drug resistance infections and drug toxi-
cities have been reported in long period applications as
well as the cost burden [6].
A well-established mechanism in the treatment of viral
pathogens is to block the binding of virus to the recep-
tor(s) and consequently prevent the penetration [29].
HBsAg is a HBV product in chronic infections which plays
an important role in pathogenesis of HBV and modulation
of host immune responses [2]. HBV is translated into three
major surface antigens including Large HBsAg (LHBsAg),
& Ali Memarian
alimemarian@goums.ac.ir
1 School of Medicine, Golstan University of Medical Sciences,
Gorgan, Iran
2 Department of Molecular Medicine, Faculty of Advanced
Medicine, Golestan University of Medical Sciences, Gorgan,
Iran
3 Stem Cell Research Center, Deputy of Research and
Technology, Golestan University of Medical Sciences,
Gorgan, Iran
123
VirusDis.
DOI 10.1007/s13337-016-0333-9
Medium (MHBsAG) and Small (SHBsAg) according to the
position of start codon within the open reading frame. Pre-
S1 is a highly conserved domain within LHBsAg which
plays a key role in recognizing and binding to the specific
receptor molecules on the host cells receptors [19, 28]. In
addition to preS1, preS2 domain of LHBS is involved in
the interaction with known HBV co-receptors such as
Fibronectin (FN) and Ferritin Light Chain (FTL). The viral
ligands (preS1 and preS2) and cellular receptors and co-
receptors such as Squamous Cell Carcinoma Antigen 1
(SCCA1) and FTL complex facilitate the penetration of
viral particles into the cell [8, 41]. Over expression of
SCCA1 is believed to increase the binding capability of
virus to the host cells. However, FTL has a potential role
for this approach [8, 18]. ASGPR and its co-receptor, FN,
and NTCP are also other proposed HBV receptor/co-re-
ceptors, which could target by drug compounds [31, 40].
Novel specific receptor blockers could result in a
noticeable decrease in the secretion of HBsAg and the
pathogenicity of HBV. HBF-0259, (7-(2-Chloro-6-fluo-
rophenyl)-5-(4-chlorophenyl)-4, 5, 6, 7-tetrahydro-tetra-
zolo [1, 5-a] pyrimidine), could act as an inhibitor of
HBsAg secretion which is proved to be efficient in certain
in vitro studies [4]. Moreover, the triazole derivates of this
compound have similar anti-HBV effects [38, 39]. Anti-
HBV potential of this non-toxic compound are hypothe-
sized to be result of HBsAg inhibition through direct
interaction with the viral or host molecules [4, 38, 42].
Cyclophilin A (CypA), Annexin II, and Ras-Associated
Protein 7 (Rab7) are known cellular components involved
in HBsAg secretion (Table 1). In order to have a precise
perspective over the underlying molecular mechanism
involved in HBsAg secretion inhibition, cellular compo-
nents involved in this process should be analyzed sepa-
rately and also in a network.
In this study, in order to predict the mechanism(s) of
action by which HBF-0259 decreases HBsAg secretion, we
predict the interaction of HBF-0259 with suggested HBV
receptors, preS regions of HBsAg (preS121–47 and
preS21–11) and cellular HBsAg secreting factors by com-
putational approaches (Table 1).
Materials and methods
Preparation of HBV cellular receptors and co-
receptors, HBF-0259, CypA and the inhibitors
ACD/ChemSketch software (ACDLABS 12.0, Toronto,
Canada) was used to design and refine the tautomer and 3D
structure of HBF-0259. The structures of four CypA inhibi-
tors, Alisporivir, NIM811, SCY635, and Sanglifehrin A were
obtained in SDF format from ChemSpider database [23]. As
shown in Table 1, the sequences and validated structures of
CypA, Annexin II, and Rab7 as well as relative HBV recep-
tors were obtained from protein databank (PDB) [1]. The
crystallographic structure of molecules were cleared for the
presence of water atoms and other unnecessary extra chains
using UCSF Chimera 1.8.1 [25] and the results were saved in
PDB format as separate files. The amino acid sequences of
PreS121–47 and PreS21–11 domains were obtained from Uni-
ProtKB Swiss-Prot database [33] (UniProt Entry: P03141).
These sequences were then used for De Novo prediction of
3D structures in Pep-Fold server [16]. The amino acid
sequence ofNTCPwas also obtained fromUniProtKB Swiss-
Prot database (UniProt Entry: Q12908) and used in for
homology based 3D structure prediction RaptorX server [24].
The predicted structures were finally validated by
Ramachandran plot in RAMPAGE server (Fig. 1) [14].
Docking software and parameters
Standalone software Hex 8.0.0 (Team Orpailleur, Nancy,
France) was used to dock HBF0259 ligand with predicted
HBV receptors. We also used Hex 8.0.0 in docking of
HBF-0259 together with any of Alisporivir, NIM811,
SCY635 and Sanglifehrin A compounds in correlation with
secretory molecules. Since ASGPR/FNIII1 and SCCA1/
Table 1 HBV ligands and their
cognate receptors and co-
receptors with PDB IDs
Viral ligands (ref) Receptors (ref)/HBsAg secreting factorsa (ref) PDB ID (ref)
Pre-S1 [8, 31] ASGPRCRD [41] and SCCA1 [8] 1DV8 [17] and 2ZV6 [43]
Pre-S2 [3, 8] FTL [8] and FNIII1 [41] 2FG4 [35] and 2HA1 [34]
Pre-S1 [20] NTCP [40] UA
HBsAg [13] Annexin II [13] 1W7B (UA)
HBsAg [10] Rab7 [10] 1YHN [36]
HBsAg [26] Cyclophilin A [26] 1BCK [11]
ASGPRCRD Asialoglycoprotein carbohydrate recognition domain, SCCA1 human Squamous cell carci-
noma antigen 1, FTL Ferritin light chain, FNIII1 Fibronectin III class 1, ref Reference, PDB Protein
DataBank, UA unavailable
a HBsAg secretory factors are Annexin II, Rab7, and Cyclophilin A
A. Mohebbi et al.
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FTL complexes are involved in binding to HBV [8, 41], the
HBF-0259 binding energy of these complexes were eval-
uated. Hex 8.0.0 was also used to form the protein–protein
complexes in the presence or absence of HBF0259 and
with PreS1 and PreS2 binding domains. Correlation Type
and FFT Mode software parameters were changed to
Shape ? Electro ? DARS and 5D, respectively. CypA,
Annexin II, and Rab7 molecules were considered as
receptors, while HBF-0259 and CypA inhibitors were
investigated as ligands.
Positioning the binding sites of HBF0259 HBV
receptors and secreting factors
The results of each receptor, co-receptor, and viral ligand
docking with HBF-0259 were analyzed by MGLTools 1.5.6
software (The Scripps Research Institute, California, USA)
for determining amino acids in HBF-0259 binding site. The
interaction analysis between HBF-0259 and possible HBV
receptors in the setting of MGLTools were done according
to VDW scaling factor 1 A˚ and the amino acid posi-
tion(s) of all binding sites were determined and investigated
in UniProt (30) regarding the molecular domains. The
binding sites for HBF0259 and CypA to Cyclophilin A
inhibitors were evaluated in the same way. Catalytic Site
Atlas (CSA) 2.0 and Allosteric ASBench (ASD/ASBench)
databases were also mined for anycatalytic sites, esteric and
orthosteric residues within macromolecules [7, 9].
Alignment
Amino acids resulted from binding site analyses were used
for ClustalW alignment by CLS Sequence Viewer version
7.5 (QIAGEN Company, USA) software. Briefly, the
amino acid sequences of the ligand binding sites were
imported to the CLS software manually. Graphic maps of
aligned amino acids were drawn using the ClustalW tool
and analyzed for the presence of any consensus sequence.
Results
Assessment of HBF-0259 interactions with HBV
receptors
As shown in Table 2, the HBF-0259 compound has the
greatest interaction energy (total energy) to SCCA1
(-499.68 kcal/mol) in comparison to all other receptors
and co-receptors. The HBF-0259 Etot to PreS121–47
(-130.11 kcal/mol) and PreS21–11 (-288.22 kcal/mol)
were also lower comparing to other predicted receptors.
These results indicate that HBF-0259 interacts more
strongly with SCCA1 and could be introduced as a more
effective receptor blocker with probable negative influence
on recognition, binding and penetration of HBV to the host
cell with therapeutic benefits. No hits were found in CSA
and ASD/ASBench databases for any of these molecules.
Among different HBsAg secreting molecules, HBF-
0259 interact CypA with higher interaction energy
The interaction energy of HBF-0259 to CypA
(-545.41 kcal/mol) was obviously higher than Annexin II
(-355.10) and Rab7 (-381.99 kcal/mol). We also com-
pared interaction energy of four other CypA inhibitors with
HBF-0259 (Table 3). The energy of Alisporivir, NIM811,
Fig. 1 Ramachandran plot
validation of predicted
structures; a 100 % NTCP84-
165 residues are in favoured
(97.5 %) and allowed (2.5 %)
zones. b preS21-11 residues
were 100 % present in favoured
area, c preS121-47 residues with
95.8 % occurrences in favor
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SCY635, and Sanglifehrin A were very close to each other
with average lower than that of HBF-0259
(-436.12 ± 3.75 kcal/mol). For HbsAg secreting mole-
cules no entries were found in CSA and ASD/ASBench
databases, but Rab7 Leu67 in its catalytic site.
HBF-0259 interaction sites within HBV receptors,
co-receptors, and viral ligands
The HBF0259 receptor binding sites of interest were
studied for the type of amino acids. Amino acids involved
in interaction site of HBF-0259 were analyzed for con-
servancies among target molecules including, SCCA1,
FNIII1, preS21–11, NTCP84–165, FTL, ASGPRCRD,
preS121–47. The results showed no conserved sequences in
any of mentioned receptors (Table 2).
The similarity of HBF-0259 binding site to CypA
in comparison with Alisporivir and NIM811
Among three cellular secreting molecules, Annexin II,
Rab7, and CypA, HBF-0259 had the highest Etot for
CypA. Therefore, CypA was selected to study the HBF-
0259 binding site in comparison to the other four CypA
inhibitors including Alisporivir, NIM811, SCY635 and
Sanglifehrin A. As shown in Table 4, HBF-0259 have
common binding site with Alisporivir in amino acids R, F,
and with NIM811 in R, H, and G. Sanglifehrin A and
SCY635 had no similar sequences neither with each other
nor other inhibitors, but Alisporivir and NIM811 had five
analogous amino acids in their binding sites including, H,
R, N, G, and T.
HBF-0259 binds to HBV Receptor/Co-receptor
Complexes with lower energies than receptors or co-
receptors alone
The AAs on the HBF-0259 binding site within SCCA1/
FTL complex were S, K, L, E, K, and T, which interact
with -173.05 kcal/mol. The HBF-0259 binding site within
NTCP84–165 was similar to preS121–47 and the AAs con-
tained in this contact were S, F, Q, V, W, K, G, and S with
209.65 kcal/mol interaction energy. The AAs in HBF-0259
binding site for ASGPR/FNIII1 complex were K, P, G, T,
E, P, Q, and Y157 which could makes -291.60 kcal/mol.
None of the mentioned amino acids were individually
identical to receptors and co-receptors. The binding energy
of these complexes showed a dramatic decrease comparing
to docking results of HBF-0259 with each receptor alone.
HBF-0259 could reduce affinity of the receptor-co-
receptor interactions which is necessary for HBV
cell entry
Different potential states of HBF-0259 binding to SCCA1/
FTL and ASGPRCRD/FNII1 protein complexes as recep-
tors for viral ligands were studied. Etot of receptors and co-
receptors, as well as ligand interactions in the presence
and/or absence of HBF-0259 were obtained (Table 5). In
the presence of HBF-0259 the Interaction energy of FTL
and PreS121–47 to SCCA1 is lower. Similarly, when
PreS121–47 and/or FTL are bound to HBF-0259 the total
energy is reduced. The interaction energy of pre-S121–47 to
ASGPRCRD in the presence of HBF-0259 was reduced
Table 2 ClustalW alignment of HBF-0259 binding sites and docking total energy
HBV receptors, co-
receptors and ligands
Amino acid residues within interaction site of HBF-0259 Total Energy
(Kcal/mol)
SCCA1 – – – S L G L F V H Q F V -499.68
FNIII1 – – – W R P R W K Y – – – -352.89
preS2 – – – – M Q S T H – – – – -288.22
NTCP84–165 F I L V I G T A I – – – – -260.26
FTL – – – – Q K K A K – – – – -215.78
ASGPRCRD – – – – S G N V T Y R – – -130.72
preS1 – – – P S N N W P – – – – -130.11
Table 3 Interaction energy of HBF-0259 to HBsAg secreting
molecules and its energy to CypA in comparison with other four
CypA inhibitors
Molecule HBF-0259 Interaction Energy (Kcal/mol)
CypA -545.41
Annexin II -355.10
Rab7 -381.99
CypA inhibitors Interaction Energy to CypA (Kcal/mol)
HBF-0259 -545.41
Alisporivir -439.93
NIM811 -438.75
SCY635 -432.40
Sanglifehrin A -433.41
A. Mohebbi et al.
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either (Table 5, Fig. 2). With existence of HBF-0259, the
PreS121–47 interaction energy to NTCP84–165 was clearly
lower.
Discussion
Current treatment strategies for HBV, as the most impor-
tant causative agent of viral hepatitis, cirrhosis, and HCC
have not meet in complete removal of the virus. Recent
studies on virus cell counterparts and HBsAg secretory
factors could make us capable to get advantages. To
achieve this goal, we performed molecular docking and
computational simulation for predicting mechanism(s) of
action of this recently developed lead-like compound,
HBF-0259. Among known cellular receptors involved in
virus integration, SCCA1 and its cellular cognate, FTL, are
reported to be overexpressed in HBV infection. Moreover,
the interaction of these receptors with viral ligands PreS1
and PreS2 facilitates virus entry [8, 37]. HBF-0259 was
presumed to have an inhibitory effect over the virus entry
by blocking SCCA1 and FTL receptor and co-receptor. For
this purpose, molecular docking was performed and the
interaction energy of each receptor and co-receptor in
conjunction with HBF-0259 was calculated.
The interaction energy between HBF-0259 and SCCA1
was high (-499.68 kcal/mol) among all other cellular
receptors. The interaction energy of HBF-0259 to
PreS121–47 and PreS21–11 were lower comparing to other
predicted receptors. HBF-0259 obviously interacts more
strongly with SCCA1. The powerful interaction of a ligand
to a receptor is compulsory in designing effective receptor
blockers. The common binding site in SCCA1 for HBF-
0259 and FTL (in SCCA1/FTL complex) could explain
energy reduction from -499.68 to -173.05 kcal/mol
(Table 3; Fig. 2). On the other hand, according to the lower
interaction energy of HBF-0259 to PreS121–47 and FTL,
also with SCCA1 higher affinity (in FTL/SCCA1 com-
plex), PreS121–47 and FTL are probably not HBF-0259
targets. Regarding other HBF-0259 binding sites, the
interaction energy of HBF-0259 was lower for FNIII1 than
ASGPRCRD and FTL. Interaction energy of FNIII1-HBF-
0259 complex to ASGPRCRD shows significant decrease
in comparison to the state of HBF-0259 absence (Table 2).
The docking results of HBF-0259 to NTCP84–165 [12] also
showed minimal interaction energy. Reduction of this
interaction energy in the presence of HBF-0259 might be a
result of the same binding sites within the receptors.
Therefore, HBF-0259 could be introduced as an effective
receptor blocker with probable negative influence on
Table 4 Interaction site of
HBF-0259 and four known
CypA inhibitors within CypA
Compounds AAs presented in interaction site within CypA
HBF-0259 R F M H F1 K G
Alisporivir Q H R I F N G T A N G Q L H R N
NIM811 H R T R H N G T K A N G
Sanglifehrin A P P T A K E R G S R
SCY635 F R R T G E K D1 Q L E
Table 5 Total energy (Etot)a of receptor, co-receptor and ligand interactions in the presence and or absence of HBF-0259
Pre-S1 Pre-S1-HBF-0259 Pre-S2 Pre-S2/HBF-0259 FTL FTL/HBF-0259 FNIII1 FNIII1/HBF-0259
SCCA1 -519.28 -571.27 NP NP -795.72 -826.65 NP NP
SCCA1/HBF-0259 -469.01 -491.54 NP NP -690.32 -523.80 NP NP
FTL NP NP -488.28 -376.38 NP NP NP NP
FTL/HBF-0259 NP NP -507.62 -329.18 NP NP NP NP
ASGPRCRD -263.58 -149.60 NP NP NP NP -745.57 -537.86
ASGPRCRD/
HBF-0259
-214.15 -49.93 NP NP NP NP -756.92 -523.80
FNIII1 NP NP -509.19 -484.10 NP NP NP NP
FNIII1/HBF-0259 NP NP -539.81 -346.72 NP NP NP NP
NTCP84–165 -439.82 -431.13 NP NP NP NP NP NP
NTCP-HBF0259 -368.16 -213.44 NP NP NP NP NP NP
The slashes (/) show the complex. For example SCCA1/HBF-0259 implicate that SCCA1 is bound to HBF-0259
a Hex 8.0.0 Total Energy (Kcal/mol)
NP not possible
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recognition, binding and penetration of HBV to the host
cell with therapeutic benefits by blocking SCCA1.
The HBF-0259 mechanism of effect on HBsAg secre-
tion inhibition is still unknown [4, 42]. For this, we per-
formed docking on known cellular factors involved in
HBsAg and HBV particle secretion including CypA,
Annexin II and Rab7 [10, 13, 26]. Our results showed that
the interaction energy of HBF-0259 to CypA
(-545.41 kcal/mol) was obviously higher than Annexin II
and Rab7 (Table 3). CypA is a peptidyl- proline cis to trans
isomerase in the cells and is believed to have a role in the
pathogenesis of some diseases [5, 21] which make it a
potent molecule for therapeutic approaches [22]. Tian et al.
[30] demonstrated the synergic role of HBV in increasing
cellular CypA and its action in HBsAg secretion. As
mentioned previously [21], CypA has a key role in life
cycle and pathogenesis of several viruses, such as Human
Immunodeficiency virus type 1(HIV-1), Hepatitis C virus
(HCV), and HBV. It could be suppressed by CypA inhi-
bitors (Alisporivir, NIM811), which their anti-HCV activ-
ities studied previously [15, 27]. According to the
comparable interaction between these inhibitors and HBF-
0259 to CypA (in both positions and interaction energies,
Tables 3 and 4), HBF-0259 could be introduced as a new
candidate for further investigation in antiviral therapies.
CypA and SCCA1 molecules probably are targeted by
HBF-0259, followed by consequent inhibition of HBsAg.
Studies with animal models or siRNA interfering and
in vitro experiments with live viruses could be so useful
for investigating HBF-0259 mechanism of action more
deeply.
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